nach oben

Annals of Nuclear Medicine

Erschienen in:

01.02.2011 | Original Article

Determination of the survival rate in patients with congestive heart failure stratified by ¹²³I-MIBG imaging: a meta-analysis from the studies performed in Japan

verfasst von: Yoichi Kuwabara, Nagara Tamaki, Tomoaki Nakata, Shohei Yamashina, Junichi Yamazaki

Erschienen in: Annals of Nuclear Medicine | Ausgabe 2/2011

Einloggen, um Zugang zu erhalten

Abstract

Background

The goals of this meta-analysis were to determine survival rates in patients with heart failure (HF) assessed by ¹²³I-MIBG imaging results using recently published studies and to determine the prognostic value of ¹²³I-MIBG imaging.

Methods

We reviewed published cohort studies carried out in Japan that compared the prognosis of patients with their ¹²³I-MIBG activity quantified as late heart-to-mediastinum ratio (H/M) or washout rate by performing a PubMed search for articles in English up to December 2006. Studies were selected if they analyzed a clearly defined lethal outcome (cardiovascular death) using life tables to estimate the odds ratio at 24 months after enrollment.

Results

Of 158 articles related to cardiac ¹²³I-MIBG, seven referred to studies that met the inclusion criteria: 5 evaluated H/M via ¹²³I-MIBG in a total of 866 patients and 4 calculated washout rate in a total of 491 patients. A low H/M indicated a high risk of cardiac death: pooled odds ratio, 5.2; 95% confidence interval (CI) of 3.1–5.7. A high washout was also associated with lethal events with a pooled odds ratio of 2.8 (CI: 1.6–5.0). The association between washout and cardiac death was heterogeneous (Chi-square = 11.0, P < 0.02), whereas that between late H/M and fatal events was homogeneous (Chi-square = 2.3, P = no significance).

Conclusion

This meta-analysis of published studies of ¹²³I-MIBG studies conducted in Japan indicated that both a decreased cardiac ¹²³I-MIBG activity (H/M) and an increased washout rate are indicative of a poor prognosis in patients with chronic heart failure.

Wieland DM, Rosenspire KC, Hutchins GD, Van Dort M, Rothley JM, Mislankar SG, et al. Neuronal mapping of the heart with 6-[¹⁸F]fluorometaraminol. J Med Chem. 1990;33:956–64.CrossRefPubMed

Rosenspire KC, Haka MS, Van Dort ME, Jewett DM, Gildersleeve DL, Schwaiger M, et al. Synthesis and preliminary evaluation of carbon-11-meta-hydroxyephedrine: a false transmitter agent for heart neuronal imaging. J Nucl Med. 1990;31:1328–34.PubMed

Raffel DM, Corbett JR, del Rosario RB, Gildersleeve DL, Chiao PC, Schwaiger M, et al. Clinical evaluation of carbon-11-phenylephrine: MAO-sensitive marker of cardiac sympathetic neurons. J Nucl Med. 1996;37:1923–31.PubMed

Degrado TR, Zalutsky MR, Vaidyanathan G. Uptake mechanisms of meta-[¹²³I]iodobenzylguanidine in isolated rat heart. Nucl Med Biol. 1995;22:1–12.CrossRefPubMed

Nakajima K, Taki J, Tonami N, Hisada K. Decreased ¹²³I-MIBG uptake and increased clearance in various cardiac diseases. Nucl Med Commun. 1994;15:317–23.CrossRefPubMed

Bengel FM, Barthel P, Matsunari I, Schmidt G, Schwaiger M. Kinetics of ¹²³I-MIBG after acute myocardial infarction and reperfusion therapy. J Nucl Med. 1999;40:904–10.PubMed

Yamada T, Shimonagata T, Fukunami M, Kumagai K, Ogita H, Hirata A, et al. Comparison of the prognostic value of cardiac iodine-123 metaiodobenzylguanidine imaging and heart rate variability in patients with chronic heart failure: a prospective study. J Am Coll Cardiol. 2003;41:231–8.CrossRefPubMed

Patel AD, Iskandrian AE. MIBG imaging. J Nucl Cardiol. 2002;9:75–94.CrossRefPubMed

Nakata T, Miyamoto K, Doi A, Sasao H, Wakabayashi T, Kobayashi H, et al. Cardiac death prediction and impaired cardiac sympathetic innervation assessed by MIBG in patients with failing and nonfailing hearts. J Nucl Cardiol. 1998;5:579–90.CrossRefPubMed

10.

Nakata T, Wakabayashi T, Kyuma M, Takahashi T, Hashimoto A, Ogata H. Prognostic implications of an initial loss of cardiac metaiodobenzylguanidine uptake and diabetes mellitus in patients with left ventricular dysfunction. J Card Fail. 2003;9:113–21.CrossRefPubMed

11.

Kyuma M, Nakata T, Hashimoto A, Nagao K, Sasao H, Takahashi T, et al. Incremental prognostic implications of brain natriuretic peptide, cardiac sympathetic nerve innervation, and noncardiac disorders in patients with heart failure. J Nucl Med. 2004;45:155–63.PubMed

12.

Matsui T, Tsutamoto T, Maeda K, Kusukawa J, Kinoshita M. Prognostic value of repeated ¹²³I-metaiodobenzylguanidine imaging in patients with dilated cardiomyopathy with congestive heart failure before and after optimized treatments—comparison with neurohumoral factors. Circ J. 2002;66:537–43.CrossRefPubMed

13.

Momose M, Kobayashi H, Iguchi N, Matsuda N, Sakomura Y, Kasanuki H, et al. Comparison of parameters of ¹²³I-MIBG scintigraphy for predicting prognosis in patients with dilated cardiomyopathy. Nucl Med Commun. 1999;20:529–35.CrossRefPubMed

14.

Imamura Y, Fukuyama T, Mochizuki T, Miyagawa M, Watanabe K, Ehime MIBG Heart Failure Study Investigators. Prognostic value of iodine-123-metaiodobenzylguanidine imaging and cardiac natriuretic peptide levels in patients with left ventricular dysfunction resulting from cardiomyopathy. Jpn Circ J. 2001;65:155–60.CrossRefPubMed

15.

Fujimoto S, Amano H, Inoue A, Ishida S, Yamashina S, Yamashina H, et al. Usefulness of ¹²³I-metaiodobenzylguanidine myocardial scintigraphy in the prediction of cardiac events in patients with cardiomyopathy showing stabilization of symptoms or preserved cardiac function. Ann Nucl Med. 2004;18:591–8.CrossRefPubMed

16.

Merlet P, Benvenuti C, Moyse D, Pouillart F, Dubois-Randé JL, Duval AM, et al. Prognostic value of MIBG imaging in idiopathic dilated cardiomyopathy. J Nucl Med. 1999;40:917–23.PubMed

17.

Agostini D, Verberne HJ, Burchert W, Knuuti J, Povinec P, Sambuceti G, et al. I-123-mIBG myocardial imaging for assessment of risk for a major cardiac event in heart failure patients: insights from a retrospective European multicenter study. Eur J Nucl Med Mol Imaging. 2008;35:535–46.CrossRefPubMed

18.

Verberne HJ, Brewster LM, Somsen GA, van Eck-Smit BL. Prognostic value of myocardial ¹²³I-metaiodobenzylguanidine (MIBG) parameters in patients with heart failure: a systematic review. Eur Heart J. 2008;29:1147–59.CrossRefPubMed

19.

Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 1998;17(24):2815–34.

20.

Petitti DB. Meta-analysis, decision analysis, and cost-effective analysis. New York: Oxford University Press; 2000. p. 117–8.

21.

Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;15(21):1539–58.CrossRef

22.

Knickmeier M, Matheja P, Wichter T, Schäfers KP, Kies P, Breithardt G, et al. Clinical evaluation of no-carrier-added meta-[¹²³I]iodobenzylguanidine for myocardial scintigraphy. Eur J Nucl Med. 2000;27:302–7.CrossRefPubMed

23.

Farahati J, Bier D, Scheubeck M, Lassmann M, Schelper LF, Grelle I, et al. Effect of specific activity on cardiac uptake of iodine-123-MIBG. J Nucl Med. 1997;38:447–51.PubMed

24.

Verberne HJ, Habraken JB, van Eck-Smit BL, Agostini D, Jacobson AF. Variations in 123I-metaiodobenzylguanidine (MIBG) late heart mediastinal ratios in chronic heart failure: a need for standardisation and validation. Eur J Nucl Med Mol Imaging. 2008;35:547–53.CrossRefPubMed

25.

Nakajima K. Normal values for nuclear cardiology: Japanese databases for myocardial perfusion, fatty acid and sympathetic imaging and left ventricular function. Ann Nucl Med. 2010;24(3):125–35.CrossRefPubMed

26.

Yamashina S, et al. Role of MIBG myocardial scintigraphy in the assessment of heart failure: the need to establish evidence. Eur J Nucl Med Mol Imaging. 2004;31:1353.

Titel: Determination of the survival rate in patients with congestive heart failure stratified by 123I-MIBG imaging: a meta-analysis from the studies performed in Japan
verfasst von: Yoichi Kuwabara
Nagara Tamaki
Tomoaki Nakata
Shohei Yamashina
Junichi Yamazaki
Publikationsdatum: 01.02.2011
Verlag: Springer Japan
Erschienen in: Annals of Nuclear Medicine / Ausgabe 2/2011
Print ISSN: 0914-7187
Elektronische ISSN: 1864-6433
DOI: https://doi.org/10.1007/s12149-010-0452-0

Springer Medizin

Abstract

Background

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2011

Comparison of a pixelated semiconductor detector and a non-pixelated scintillation detector in pinhole SPECT system for small animal study

Is contrast material needed after treatment of malignant lymphoma in positron emission tomography/computed tomography?

F18-FDG-PET/CT thyroid incidentalomas and their benign or malignant nature: a critical and debated issue

Intestinal uptake of 99mTc-MDP: a case report of protein-losing enteropathy correlated with pathology findings from autopsy

Deep-inspiration breath-hold PET/CT versus free breathing PET/CT and respiratory gating PET for reference: evaluation in 95 patients with lung cancer

Acknowledgements to Reviewers